Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Host immunological responses facilitate development of SARS-CoV-2 mutations in patients receiving monoclonal antibody treatments
Akshita Gupta, Angelina Konnova, Mathias Smet, et al.
Journal of Clinical Investigation (2023) Vol. 133, Iss. 6
Open Access | Times Cited: 30

Showing 1-25 of 30 citing articles:

SARS-CoV-2 viral clearance and evolution varies by type and severity of immunodeficiency
Yijia Li, Manish C. Choudhary, James Regan, et al.
Science Translational Medicine (2024) Vol. 16, Iss. 731
Open Access | Times Cited: 48
Sotrovimab: A Review of Its Efficacy against SARS-CoV-2 Variants
Daniele Focosi, Arturo Casadevall, Massimo Franchini, et al.
Viruses (2024) Vol. 16, Iss. 2, pp. 217-217
Open Access | Times Cited: 17
SARS-CoV-2 variants resistant to monoclonal antibodies in immunocompromised patients constitute a public health concern
Arturo Casadevall, Daniele Focosi
Journal of Clinical Investigation (2023) Vol. 133, Iss. 6
Open Access | Times Cited: 31
Analysis of SARS-CoV-2 mutations associated with resistance to therapeutic monoclonal antibodies that emerge after treatment
Daniele Focosi, Scott A. McConnell, David J. Sullivan, et al.
Drug Resistance Updates (2023) Vol. 71, pp. 100991-100991
Open Access | Times Cited: 31
Effect of molnupiravir on SARS-CoV-2 evolution in immunocompromised patients: a retrospective observational study
Nicholas M. Fountain‐Jones, Robert Vanhaeften, Jan Williamson, et al.
The Lancet Microbe (2024) Vol. 5, Iss. 5, pp. e452-e458
Open Access | Times Cited: 12
SARS-CoV-2 resistance to monoclonal antibodies and small-molecule drugs
Sho Iketani, David D. Ho
Cell chemical biology (2024) Vol. 31, Iss. 4, pp. 632-657
Open Access | Times Cited: 7
VEGF-A plasma levels are associated with impaired DLCO and radiological sequelae in long COVID patients
Aurélien Philippe, Sven Günther, Jeanne Rancic, et al.
Angiogenesis (2023) Vol. 27, Iss. 1, pp. 51-66
Closed Access | Times Cited: 15
TrkB Agonist (7,8-DHF)-Induced Responses in Dorsal Root Ganglia Neurons Are Decreased after Spinal Cord Injury: Implication for Peripheral Pain Mechanisms
Kyeongran Jang, Sandra M. Garraway
eNeuro (2025) Vol. 12, Iss. 1, pp. ENEURO.0219-24.2024
Open Access
Antibody drugs targeting SARS-CoV-2: Time for a rethink?
Likeng Liang, Bo Wang, Qing Zhang, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 176, pp. 116900-116900
Open Access | Times Cited: 4
Serial Llama Immunization with Various SARS-CoV-2 RBD Variants Induces Broad Spectrum Virus-Neutralizing Nanobodies
Pavel P. Solodkov, Alexander M. Najakshin, Nikolai A. Chikaev, et al.
Vaccines (2024) Vol. 12, Iss. 2, pp. 129-129
Open Access | Times Cited: 3
Creation of Standardized Common Data Elements for Diagnostic Tests in Infectious Disease Studies: Semantic and Syntactic Mapping
Caroline Stellmach, Sina M. Hopff, Thomas Jaenisch, et al.
Journal of Medical Internet Research (2024) Vol. 26, pp. e50049-e50049
Open Access | Times Cited: 3
Considerations for the development of monoclonal antibodies to address new viral variants in COVID-19
Arturo Casadevall, Scott A. McConnell, Daniele Focosi
Expert Opinion on Biological Therapy (2024) Vol. 24, Iss. 8, pp. 787-797
Closed Access | Times Cited: 3
Have Diagnostics, Therapies, and Vaccines Made the Difference in the Pandemic Evolution of COVID-19 in Comparison with “Spanish Flu”?
Florigio Lista, Mario Stefano Peragallo, Roberto Biselli, et al.
Pathogens (2023) Vol. 12, Iss. 7, pp. 868-868
Open Access | Times Cited: 8
SARS-CoV-2 genomics and impact on clinical care for COVID-19
Ramon Lorenzo‐Redondo, Alexandre Machado de Sant’Anna Carvalho, Judd F. Hultquist, et al.
Journal of Antimicrobial Chemotherapy (2023) Vol. 78, Iss. Supplement_2, pp. ii25-ii36
Open Access | Times Cited: 8
Characterization of Treatment Resistance and Viral Kinetics in the Setting of Single-Active Versus Dual-Active Monoclonal Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2
Manish C Choudhary, Rinki Deo, Teresa H. Evering, et al.
The Journal of Infectious Diseases (2024) Vol. 230, Iss. 2, pp. 394-402
Closed Access | Times Cited: 2
A Robust SARS-CoV-2-specific T and B Cell Response is Associated with Early Viral Clearance in SARS-CoV-2 Omicron-Infected Immunocompromised Individuals
Magda Vergouwe, Jason J. Biemond, Karlijn van der Straten, et al.
The Journal of Infectious Diseases (2024)
Open Access | Times Cited: 2
SARS-CoV-2 Viral Clearance and Evolution Varies by Extent of Immunodeficiency
Yijia Li, Manish C. Choudhary, James Regan, et al.
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 6
Immunogenicity and reactogenicity of a first booster with BNT162b2 or full-dose mRNA-1273: A randomised VACCELERATE trial in adults ≥75 years (EU-COVAT-1)
Julia Neuhann, Jannik Stemler, Antonio J. Carcas, et al.
Vaccine (2023) Vol. 41, Iss. 48, pp. 7166-7175
Open Access | Times Cited: 6
Anti SARS-CoV-2 Monoclonal Antibodies in Pre-Exposure or Post-Exposure in No- or Weak Responder to Vaccine Kidney Transplant Recipients: Is One Strategy Better than Another?
Anais Romero, Charlotte Laurent, L Lebourg, et al.
Viruses (2024) Vol. 16, Iss. 3, pp. 381-381
Open Access | Times Cited: 1
Interleukin‐2‐mediated CD4 T‐cell activation correlates highly with effective serological and T‐cell responses to SARS‐CoV‐2 vaccination in people living with HIV
Akshita Gupta, Elda Righi, Angelina Konnova, et al.
Journal of Medical Virology (2024) Vol. 96, Iss. 8
Open Access | Times Cited: 1
Persistent COVID-19 Infection in an Immunocompromised Host: A Case Report
Rashmita Das, Rajesh Karyakarte, Suvarna Joshi, et al.
Cureus (2024)
Open Access | Times Cited: 1
Analysis of SARS-CoV-2 mutations associated with resistance to therapeutic monoclonal antibodies that emerge after treatment
Daniele Focosi, Scott A. McConnell, David J. Sullivan, et al.
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 4
SARS-CoV-2 evolution during persistent infection in a CAR-T recipient shows an escape to both sotrovimab and T-cell responses
Paola Mazzetti, Pietro Giorgio Spezia, Anna-Lisa Capria, et al.
Journal of Clinical Virology Plus (2023) Vol. 3, Iss. 2, pp. 100149-100149
Open Access | Times Cited: 4
Prevalence of SARS-CoV-2 Omicron Sublineages and Spike Protein Mutations Conferring Resistance against Monoclonal Antibodies in a Swedish Cohort during 2022–2023
Jonathan Haars, Navaneethan Palanisamy, Frans Wallin, et al.
Microorganisms (2023) Vol. 11, Iss. 10, pp. 2417-2417
Open Access | Times Cited: 3
Anti-SARS-CoV-2 glyco-humanized polyclonal antibody XAV-19: phase II/III randomized placebo-controlled trial shows acceleration to recovery for mild to moderate patients with COVID-19
Garyphallia Poulakou, Pierre‐Joseph Royer, Nikolay Evgeniev, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access
Page 1 - Next Page

Scroll to top